Wall Street brokerages expect Nevro Corp (NYSE:NVRO) to announce earnings of ($0.81) per share for the current quarter, according to Zacks. Five analysts have made estimates for Nevro’s earnings. The lowest EPS estimate is ($0.97) and the highest is ($0.47). Nevro reported earnings of ($0.37) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 118.9%. The firm is expected to report its next earnings report on Monday, November 4th.

On average, analysts expect that Nevro will report full-year earnings of ($3.87) per share for the current financial year, with EPS estimates ranging from ($4.26) to ($3.36). For the next financial year, analysts expect that the company will post earnings of ($2.83) per share, with EPS estimates ranging from ($3.81) to ($1.35). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Nevro.

Nevro (NYSE:NVRO) last issued its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.02). Nevro had a negative return on equity of 39.62% and a negative net margin of 24.51%. The firm had revenue of $93.60 million for the quarter, compared to the consensus estimate of $88.40 million. During the same period last year, the firm earned ($0.35) EPS. The company’s revenue for the quarter was down 2.6% on a year-over-year basis.

Several brokerages have issued reports on NVRO. Morgan Stanley set a $76.00 price target on Nevro and gave the stock a “buy” rating in a research note on Friday, August 9th. ValuEngine raised Nevro from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 24th. Zacks Investment Research raised Nevro from a “sell” rating to a “hold” rating and set a $67.00 target price for the company in a research note on Tuesday. Bank of America boosted their target price on Nevro from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Northland Securities set a $65.00 target price on Nevro and gave the company a “hold” rating in a research note on Friday, August 9th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Nevro currently has a consensus rating of “Hold” and a consensus target price of $62.91.

NVRO stock traded down $2.04 during mid-day trading on Thursday, hitting $80.79. 812,000 shares of the stock were exchanged, compared to its average volume of 578,017. The company has a debt-to-equity ratio of 0.83, a current ratio of 6.30 and a quick ratio of 4.87. The business has a fifty day moving average price of $65.88 and a 200 day moving average price of $59.24. Nevro has a 12 month low of $34.75 and a 12 month high of $83.57. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -49.26 and a beta of 0.29.

In other Nevro news, Director Elizabeth H. Weatherman purchased 2,460 shares of Nevro stock in a transaction that occurred on Friday, June 7th. The shares were bought at an average price of $60.99 per share, for a total transaction of $150,035.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Kevin C. Oboyle purchased 1,675 shares of Nevro stock in a transaction that occurred on Wednesday, June 5th. The shares were acquired at an average price of $60.00 per share, for a total transaction of $100,500.00. The disclosure for this purchase can be found here. 7.60% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the stock. Advisor Group Inc. grew its position in shares of Nevro by 64.5% in the fourth quarter. Advisor Group Inc. now owns 921 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 361 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Nevro by 9.3% in the fourth quarter. Geode Capital Management LLC now owns 308,995 shares of the medical equipment provider’s stock valued at $12,016,000 after purchasing an additional 26,356 shares in the last quarter. Two Sigma Investments LP grew its position in shares of Nevro by 86.9% in the fourth quarter. Two Sigma Investments LP now owns 7,474 shares of the medical equipment provider’s stock valued at $291,000 after purchasing an additional 3,474 shares in the last quarter. Legal & General Group Plc grew its position in shares of Nevro by 31.2% in the fourth quarter. Legal & General Group Plc now owns 12,886 shares of the medical equipment provider’s stock valued at $502,000 after purchasing an additional 3,065 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Nevro in the fourth quarter valued at $36,675,000.

Nevro Company Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Story: What is a Candlestick Chart?

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.